Cheetah Medical Set To Compete In Fast-Growing Hemodynamic Monitoring Market
This article was originally published in Start Up
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently.
You may also be interested in...
Edwards Lifesciences announced that it was acquiring private Dutch company BMEYE BV, the developer of a new noninvasive technology for hemodynamic monitoring. Noninvasive hemodynamic monitoring has long been “The Holy Grail” in critical care, and non-invasive technology opens up new applications and new markets for Edwards as well.
While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.
Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.